Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Switzerland
  4. Swiss Exchange
  5. Bachem Holding AG
  6. News
  7. Summary
    BANB   CH0012530207

BACHEM HOLDING AG

(BANB)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Bachem : recognized as a winner at the Swiss Biotech Success Stories Awards 2021

06/08/2021 | 02:51am EDT

Bachem is excited to announce that the company has been recognized as one of the five winners of the Swiss Biotech Success Stories Awards 2021.

The awards, bestowed by the Swiss Biotech Association, celebrates those who have made important and sustainable contributions to the biotech industry in Switzerland.

Bachem is a world leader in the manufacturing of peptides and is expanding into oligonucleotides - both are highly complex drug substances that are increasingly used in modern medicine. The company was founded in Switzerland and has sites in Vionnaz and Bubendorf, as well as sites in the UK, the US and an office in Japan.

'I am happy that Bachem has won a Swiss Biotech Success Stories Award. Within fifty years, we have grown from a small company of two people to a leading provider for the world's biopharmaceutical industry. This award is a testament to the team of talented and dedicated people that are the foundation of Bachem's long-term success. I would like to thank the Swiss Biotech Association for this recognition.

We are proud of our strong Swiss heritage as we are of the strong global impact we can make for our customers and ultimately patients worldwide.

At Bachem, we take a long-term approach and continue to see broad-based growth, both in terms of products and geography. Despite the challenges of the ongoing COVID-19 pandemic, we continue to build new production capabilities and hire people across all our sites.'

Thomas Meier

CEO,Bachem AG

'The tag for our initiative is Success Stories, but what we really mean is Value! Bachem is an entrepreneurial story that consistently created value for the last 50 years in Switzerland and abroad. Like with the current laureates and the one to come, it is important to celebrate valuable achievements within the life sciences ecosystem but it is also essential to share it with the public to educate, and the young generations as a palatable path forward for their future.'

Luca Bolliger

President of the Jury,Swiss Biotech Success Stories

Success categories

Bachem was chosen as a winner due to a number of success categories, including:

  • Completed achievement with lasting impact
  • Creation of jobs in Switzerland
  • Enabler for the biotech industry
  • Involvement of one or more Swiss citizens
  • Product approval and sustainable revenues
  • Swiss-based company / institution
  • Swissness: Think global, made in Switzerland

The company is honored to be recognized by the association and will attend the Swiss Biotech Day event on September 7 in Basel where the award will be collected personally.

About the Swiss Biotech Association

Founded in 1998, the Swiss Biotech Association represents the interests of the Swiss biotech industry. To support its members in a competitive market, the Swiss Biotech Association works to secure favorable framework conditions and facilitate access to talents, novel technologies and financial resources. To strengthen and promote the Swiss biotech industry, the Swiss Biotech Association collaborates with numerous partners and life science clusters globally under the brand Swiss Biotech™.

About Bachem

Bachem is a leading, innovation-driven company specializing in the development and manufacture of peptides and oligonucleotides.

With 50 years of experience and expertise Bachem provides products for research, clinical development and commercial application to pharmaceutical and biotechnology companies worldwide and offers a comprehensive range of services.

Bachem operates internationally with headquarters in Switzerland and locations in Europe, the US and Asia. The company is listed on the SIX Swiss Exchange.

Disclaimer

Bachem Holding AG published this content on 08 June 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 08 June 2021 06:50:04 UTC.


ę Publicnow 2021
All news about BACHEM HOLDING AG
06/17BACHEMá : Mirabaud Securities Lifts Price Target on Bachem, Maintains Buy Recomm..
MT
06/15BACHEMá : A world market leader from the Basel region – Bachem celebrates ..
PU
06/14BACHEMá : What are Amino Acids?
PU
06/10BACHEMá : Antimicrobial Peptides
PU
06/08BACHEMá : recognized as a winner at the Swiss Biotech Success Stories Awards 202..
PU
06/04BACHEMá : What is GMP?
PU
05/27BACHEMá : Amyloid Beta Peptides & Alzheimer's Disease
PU
05/27PRESS RELEASE : Santhera Publishes Agenda for its Annual General Meeting
DJ
05/25BACHEMá : Will Targeting Alpha-Synuclein Lead to Treatments for Parkinson's Dise..
PU
05/11MEET BACHEM : Swetlana Meinhardt, Category Manager
PU
More news
Financials
Sales 2021 479 M 522 M 522 M
Net income 2021 101 M 110 M 110 M
Net Debt 2021 146 M 159 M 159 M
P/E ratio 2021 72,1x
Yield 2021 0,67%
Capitalization 7 292 M 7 954 M 7 938 M
EV / Sales 2021 15,5x
EV / Sales 2022 13,2x
Nbr of Employees 1 475
Free-Float 42,9%
Chart BACHEM HOLDING AG
Duration : Period :
Bachem Holding AG Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends BACHEM HOLDING AG
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 4
Average target price 501,67 CHF
Last Close Price 521,00 CHF
Spread / Highest target 15,2%
Spread / Average Target -3,71%
Spread / Lowest Target -24,2%
EPS Revisions
Managers and Directors
NameTitle
Thomas Meier Chief Executive Officer
Alain Schaffter Chief Financial Officer
Kuno Sommer Chairman
GŘnther Loidl Chief Technology Officer
Ralph Sch÷nleber Vice President-Research & Development
Sector and Competitors
1st jan.Capitalization (M$)
BACHEM HOLDING AG31.73%7 954
MODERNA, INC.93.81%81 297
LONZA GROUP AG15.68%53 313
IQVIA HOLDINGS INC.37.47%47 206
CELLTRION, INC.-25.07%32 426
SEAGEN INC.-12.42%27 835